Efficacy and Safety of [
225Ac and 177Lu
PSMA radioligand therapy
biochemical response
efficacy
metastatic castration-resistant prostate cancer
molecular imaging response
toxicity
Journal
Pharmaceutics
ISSN: 1999-4923
Titre abrégé: Pharmaceutics
Pays: Switzerland
ID NLM: 101534003
Informations de publication
Date de publication:
14 May 2021
14 May 2021
Historique:
received:
08
04
2021
revised:
26
04
2021
accepted:
07
05
2021
entrez:
2
6
2021
pubmed:
3
6
2021
medline:
3
6
2021
Statut:
epublish
Résumé
The use of
Identifiants
pubmed: 34069003
pii: pharmaceutics13050722
doi: 10.3390/pharmaceutics13050722
pmc: PMC8156464
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Oncotarget. 2017 Jan 10;8(2):3581-3590
pubmed: 27683041
Lancet. 2010 Oct 2;376(9747):1147-54
pubmed: 20888992
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):103-112
pubmed: 32378019
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):721-728
pubmed: 31758224
J Nucl Med. 2016 Aug;57(8):1170-6
pubmed: 26985056
J Med Imaging Radiat Sci. 2019 Dec;50(4 Suppl 1):S58-S65
pubmed: 31427258
J Cell Biochem. 2004 Feb 15;91(3):528-39
pubmed: 14755683
Prostate. 2018 May;78(7):491-497
pubmed: 29436722
N Engl J Med. 2013 Jul 18;369(3):213-23
pubmed: 23863050
J Nucl Med. 2020 Jun;61(6):857-865
pubmed: 31732676
Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1200-1210
pubmed: 32970216
Int J Clin Pract. 2011 Nov;65(11):1180-92
pubmed: 21995694
Cancers (Basel). 2021 Feb 13;13(4):
pubmed: 33668474
J Nucl Med. 2019 Jul;60(7):955-962
pubmed: 30683770
Clin Genitourin Cancer. 2017 Feb;15(1):60-66.e2
pubmed: 27692812
Target Oncol. 2021 May;16(3):369-380
pubmed: 33687624
Eur J Nucl Med Mol Imaging. 2021 Jan;48(1):113-122
pubmed: 32383093
Eur Urol. 2020 Aug;78(2):148-154
pubmed: 32532512
J Clin Oncol. 2016 Apr 20;34(12):1402-18
pubmed: 26903579
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):687-694
pubmed: 31901103
Indian J Nucl Med. 2020 Oct-Dec;35(4):299-304
pubmed: 33642753
Oncotarget. 2016 Mar 15;7(11):12477-88
pubmed: 26871285
Nat Rev Cancer. 2015 Dec;15(12):701-11
pubmed: 26563462
Eur Urol. 2015 Aug;68(2):325-34
pubmed: 25108577
Eur Urol. 2021 Mar;79(3):343-350
pubmed: 33293081
J Nucl Med. 2020 Jan;61(1):62-69
pubmed: 31101746
Radiology. 2016 Jul;280(1):151-60
pubmed: 26807894
Theranostics. 2019 Jul 9;9(17):4841-4848
pubmed: 31410185
Eur J Nucl Med Mol Imaging. 2020 Sep;47(10):2322-2327
pubmed: 32140802
J Nucl Med. 2009 May;50 Suppl 1:122S-50S
pubmed: 19403881
Oncotarget. 2017 Oct 7;8(61):103108-103116
pubmed: 29262549
Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):1014-1024
pubmed: 28283702
N Engl J Med. 2011 May 26;364(21):1995-2005
pubmed: 21612468
J Nucl Med. 2017 Oct;58(10):1624-1631
pubmed: 28408529
Eur J Nucl Med Mol Imaging. 2019 Jan;46(1):129-138
pubmed: 30232539
Clin Nucl Med. 2020 Dec;45(12):935-942
pubmed: 32956129
Eur J Nucl Med Mol Imaging. 2019 May;46(5):1063-1072
pubmed: 30569186
J Nucl Med. 2017 Jan;58(1):85-90
pubmed: 27765862
N Engl J Med. 2004 Oct 7;351(15):1502-12
pubmed: 15470213
Eur Urol. 2021 Feb;79(2):243-262
pubmed: 33172724
Semin Nucl Med. 2008 Sep;38(5):358-66
pubmed: 18662557
Theranostics. 2020 Jul 23;10(20):9364-9377
pubmed: 32802197
Eur Urol. 2014 Jan;65(1):3-6
pubmed: 24120464
J Nucl Med. 2016 Dec;57(12):1941-1944
pubmed: 27390158
Prostate. 2019 Sep;79(12):1462-1470
pubmed: 31334872
Eur J Nucl Med Mol Imaging. 2020 Mar;47(3):713-720
pubmed: 31781834
Lancet Oncol. 2018 Jun;19(6):825-833
pubmed: 29752180
Eur Urol Focus. 2017 Oct;3(4-5):480-486
pubmed: 28753787
N Engl J Med. 2020 May 28;382(22):2091-2102
pubmed: 32343890
N Engl J Med. 2012 Sep 27;367(13):1187-97
pubmed: 22894553
Urol Oncol. 2020 Dec 19;:
pubmed: 33353867
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nuklearmedizin. 2019 Dec;58(6):443-450
pubmed: 31724145
Eur Urol. 2014 Feb;65(2):270-273
pubmed: 24295792
Theranostics. 2021 Feb 16;11(9):4050-4060
pubmed: 33754047
J Nucl Med. 2021 May 10;62(5):669-674
pubmed: 33008928
Eur J Nucl Med Mol Imaging. 2015 Feb;42(2):328-54
pubmed: 25452219